Jane Yanagawa, MD

Jane Yanagawa, MD

Assistant Professor, Department of Surgery, Thoracic Surgery

Languages

English

Specialty

Cardiothoracic Surgery

Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica

Education

Fellowship

Research, UCLA School of Medicine, 2007 - 2009

Internship

Surgery, UCSD Medical Center, 2004 - 2005

Degree

MD, Baylor College of Medicine, 2004

Residencies

Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, 2011 - 2013
Surgery, UCSD Medical Center, 2009 - 2011
Surgery, UCSD Medical Center, 2005 - 2007

Board Certifications

Thoracic and Cardiac Surgery, American Board of Thoracic Surgery, 2014
Surgery, American Board of Surgery, 2012

Contact Information

Clinical Interests

Lung, Lung Cancer and Chest Malignancies, Lung Metastasis, Lung Nodule

Scientific Interests

Dr. Jane Yanagawa's ultimate goal as a physician-scientist is to improve long-term outcomes in patients with early-stage resectable non-small cell lung cancer. She hopes to develop a scientific portfolio in translational lung cancer research focusing on mechanisms of immune-modulation that ultimately extends to clinical trials of immunotherapies for patients with resectable lung cancer.

Highlighted Publications

Efficace F, Fayers P, Pusic A, Cemal Y, Yanagawa J, Jacobs M, la Sala A, Cafaro V, Whale K, Rees J, Blazeby J; European Organization for Research and Treatment of Cancer Quality-of-Life Group (Patient-Reported Outcome Measurements Over Time in Oncology Registry). Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. Cancer. 2015 Sep 15;121(18):3335-42. doi: 10.1002/cncr.29489. Epub 2015 Jun 16.

Lee MH, Kachroo P, Pagano PC, Yanagawa J, Wang G, Walser TC, Krysan K, Sharma S, John MS, Dubinett SM, Lee JM. Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway. J Cancer Sci Ther. 2014 Nov;6(11):468-477. Epub 2014 Nov 15.

Lin AY, Kotova S, Yanagawa J, Elbuluk O, Wang G, Kar N, Elashoff D, Grogan T, Cameron RB, Singh A, Chmielowski B, Federman N, Nelson SD, Lee P, Eilber FC, Lee JM. Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas. J Thorac Cardiovasc Surg. 2015 Jan;149(1):85-92. doi: 10.1016/j.jtcvs.2014.09.039. Epub 2014 Sep 18.

Yanagawa J, Rusch V. Surgical management of malignant pleural mesothelioma. Thorac Surg Clin. 2013 Feb;23(1):73-87, vi. doi: 10.1016/j.thorsurg.2012.10.002.

Yanagawa J, Rusch VW. Current surgical therapy for stage IIIA (N2) non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2011 Winter;23(4):291-6. doi: 10.1053/j.semtcvs.2011.12.001.